截至2025年9月5日收盘，祥生医疗（688358）报收于29.75元，较上周的31.32元下跌5.01%。本周，祥 生医疗9月1日盘中最高价报31.66元。9月4日盘中最低价报28.81元。祥生医疗当前最新总市值33.36亿 元，在医疗器械板块市值排名103/126，在两市A股市值排名4261/5152。 本周关注点 祥生医疗将于2025年9月17日15:00-17:00参加上交所主办的科创板医疗器械行业集体业绩说明会，通过 上证路演中心以网络文字互动形式召开。参会人员包括董事长莫若理、董秘周峰、财务负责人周峰、独 董李寿喜等。投资者可于9月10日至16日16:00前通过上证路演中心或公司邮箱info@chison.com.cn预提 问。 公司拟召开2025年第一次临时股东大会，审议取消监事会、修订《公司章程》并办理工商变更登记。根 据新《公司法》，监事会职权将由董事会审计委员会行使，《监事会议事规则》将废止，同步制定《会 计师事务所选聘制度》。会议采取现场与网络投票结合方式，现场会议定于2025年9月16日举行。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010434571030124 ...

Core Viewpoint - Wuxi Xiangsheng Medical Technology Co., Ltd. is actively implementing a "Quality Improvement and Efficiency Enhancement" action plan to enhance investor returns and strengthen its core competitiveness through continuous innovation and talent development [1][2]. Group 1: Innovation and R&D - The company has maintained a research and development (R&D) personnel ratio of 34.3%, with 178 R&D staff, averaging over 10 years of experience, contributing to sustained innovation [1]. - As of the reporting period, the company holds 391 authorized patents, including 158 invention patents and 99 software copyrights, demonstrating its strong R&D capabilities [2]. - The company has accelerated its international product registration process, obtaining 43 new foreign market access licenses during the reporting period, thereby expanding its overseas market share [2]. Group 2: Commercialization and Market Presence - The company showcased its full range of products and AI-assisted diagnostic solutions at over 70 global industry events, enhancing brand exposure and clinical value [2]. - The "SonoGlobal 2025" agent conference and the "Evergreen Elite Project" were launched to upgrade core partners' capabilities from product sales to solution delivery, establishing a sustainable strategic cooperation system [2]. Group 3: Investor Communication and Disclosure - The company has established a comprehensive information disclosure management system to fulfill its obligations and has actively communicated with investors through various channels [3][4]. - Regular performance briefings and visual presentations of reports have been implemented to enhance investor understanding of the company's operations [4]. Group 4: Investor Returns - Since its listing in 2019, the company has maintained an average dividend payout ratio exceeding 65%, with a total dividend distribution of RMB 464 million [5]. - For the 2024 fiscal year, the company plans to distribute cash dividends of RMB 10 per 10 shares, totaling RMB 112 million, which represents 79.62% of the net profit attributable to shareholders [5]. Group 5: Corporate Governance - The company emphasizes the importance of a sound governance structure and effective internal control systems to enhance operational compliance and decision-making [6]. - The company has organized training for key personnel to ensure compliance with regulations and improve understanding of market dynamics [6].

Group 1 - The core viewpoint of the article highlights that Wuxi Xiangsheng Medical Technology Co., Ltd. has successfully obtained the EU Medical Devices Regulation (MDR) certification for its entire range of digital color ultrasound diagnostic products, marking a significant achievement in aligning with international safety and quality standards [1][2] - The MDR certification serves as a "hard currency" for entering the EU market and provides strong international credibility for the company's expansion into potential markets in Asia-Pacific, the Middle East, and Latin America [1] - Xiangsheng Medical has established a comprehensive technological capability in ultrasound imaging, covering various aspects from core components to clinical applications, thereby creating differentiated advantages in portability, specialization, and intelligence [1][2] Group 2 - The company's products are already utilized in over 30% of tertiary hospitals in China and have been exported to more than 100 countries and regions globally, establishing solid strategic partnerships with renowned international medical device companies [2] - In the field of ultrasound AI diagnostics, Xiangsheng Medical has developed an intelligent standard framework that encompasses device research and development, image acquisition, and diagnostic decision-making, with its breast ultrasound analysis software receiving medical device registration approval in 2022 [2] - The company aims to enhance its global market penetration with the MDR certification as a new starting point, focusing on providing smarter, more precise, and more accessible ultrasound diagnostic services worldwide, thereby strengthening the "China Intelligent Manufacturing" brand in the high-end medical device sector [2]